LeonaBio, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
LeonaBio, Inc. (LONA) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $680.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-23.
Discontinued › Notes
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2023-03-23
- LeonaBio, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $0.00.
- LeonaBio, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-09-30 was $0.00.
- LeonaBio, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-06-30 was $162.00K.
- LeonaBio, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-03-31 was $518.00K.
- LeonaBio, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $680.00K, a 30.26% decline from fiscal 2020.
- LeonaBio, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $975.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $162.00K derived: sum of 3 quarters · filed 2023-03-23 | $680.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $162.00K derived: sum of 2 quarters · filed 2022-11-10 | $680.00K 10-Q · filed 2022-11-10 | $680.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $162.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $680.00K 10-Q · filed 2022-08-15 | $680.00K derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-03-31 | $518.00K 10-Q · filed 2022-05-12 | $518.00K derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $975.00K 10-K · filed 2022-03-28 | ||
| 2020-09-30 | $975.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |